Table VII.
Comparison of survival rates following neoadjuvant chemotherapy in different studies.
| Study | RFS (%) | MFS (%) | PFS (%) | OS (%) |
|---|---|---|---|---|
| Present study (NDP + GEM) | 96.6 (2-year) | 85.5 (2-year) | 83.3 (2-year) | 96.1 (2-year) |
| Du et al (37) (Docetaxel + CDDP + 5-FU) | 96.6 (2-year) | 93.3 (2-year) | 89.9 (2-year) | 98.3 (2-year) |
| Zheng et al (28) (5-FU + NDP) | – | – | 75.0 (2-year) | 88.5 (2-year) |
| Yau et al (32) (CDDP + GEM) | 78.0 (3-year) | 76.0 (3-year) | 63.0 (3-year) | 76.0 (3-year) |
| He et al (33) (CDDP + GEM) | 94.9 (3-year) | 86.2 (3-year) | – | 87.7 (3-year) |
| Kong et al (38) (Docetaxel + CDDP + 5-FU) | 100 (3-year) | 88.0 (3-year) | 85.1 (3-year) | 90.2 (3-year) |
| Ekenel et al (36) (Docetaxel + CDDP) | 84.7 (3-year) | 94.9 (3-year) | ||
| Zhong et al (35) (Docetaxel + CDDP) | 72.7 (3-year) | 94.1 (3-year) | ||
| Lim et al (30) (CBP + GEM) | 92.9 (3-year) | 89.1 (3-year) | 82.1 (3-year) | 89.3 (3-year) |
NDP, nedaplatin; GEM, gemcitabine; CBP, carboplatin; CDDP, cisplatin; 5-FU, 5-fluorouracil; RFS, recurrence-free survival; MFS, metastasis-free survival; PFS, progression-free survival; OS, overall survival.